78Q Stock Overview
A biotechnology company, develops drugs for oncology and chronic inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Philogen S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €18.90 |
| 52 Week High | €22.00 |
| 52 Week Low | €16.25 |
| Beta | 0.18 |
| 1 Month Change | 2.72% |
| 3 Month Change | -2.83% |
| 1 Year Change | 6.48% |
| 3 Year Change | 36.36% |
| 5 Year Change | n/a |
| Change since IPO | 28.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 78Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 2.5% | -0.4% |
| 1Y | 6.5% | -10.2% | 7.9% |
Return vs Industry: 78Q exceeded the German Biotechs industry which returned -10.2% over the past year.
Return vs Market: 78Q underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 78Q volatility | |
|---|---|
| 78Q Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 78Q has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 78Q's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 174 | Dario Neri | www.philogen.com |
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase II clinical trial for the treatment of chronic inflammatory disorders; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial.
Philogen S.p.A. Fundamentals Summary
| 78Q fundamental statistics | |
|---|---|
| Market cap | €741.33m |
| Earnings (TTM) | -€29.35m |
| Revenue (TTM) | €3.92m |
189.2x
P/S Ratio-25.3x
P/E RatioIs 78Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 78Q income statement (TTM) | |
|---|---|
| Revenue | €3.92m |
| Cost of Revenue | €18.91m |
| Gross Profit | -€14.99m |
| Other Expenses | €14.36m |
| Earnings | -€29.35m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | -382.55% |
| Net Profit Margin | -748.89% |
| Debt/Equity Ratio | 3.2% |
How did 78Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 07:11 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Philogen S.p.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keyur Parekh | Goldman Sachs |
| Rajan Sharma | Goldman Sachs |
| Victor Floch | Stifel, Equities Research |